Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atul Deodhar

Showing results (141-150 of 272) with videos related to

Pageof 28
Sort By:
Rheumatology and Therapy|September 11, 2024
Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 TrialsJeffrey R Curtis, Atul Deodhar, Enrique R Soriano, et al.
Arthritis and Rheumatism|December 30, 2009
Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trialClifton O Bingham, R John Looney, Atul Deodhar, et al.
Annals of the Rheumatic Diseases|September 2, 2016
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 StudyJoachim Sieper, Atul Deodhar, Helena Marzo-Ortega, et al.
The Permanente Journal|August 2, 2016
Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care SettingJeffrey R Curtis, Leslie R Harrold, Maryam M Asgari, et al.
Clinical Rheumatology|August 27, 2025
Prevalence of axial spondyloarthritis (axSpA) in patients treated for chronic back pain in chiropractic clinics: the oregon chiropractic axial spondyloarthritis study (ORCAS)Atul Deodhar, Shireesh Bhalerao, Sonam Kiwalkar, et al.
Lancet (London, England)|June 13, 2018
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyAtul Deodhar, Alice B Gottlieb, Wolf-Henning Boehncke, et al.
Arthritis Research & Therapy|March 22, 2022
Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitisM Elaine Husni, Atul Deodhar, Sergio Schwartzman, et al.
Rheumatology and Therapy|February 23, 2023
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing SpondylitisVictoria Navarro-Compán, Xenofon Baraliakos, Marina Magrey, et al.
RMD Open|October 1, 2019
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension studyXenofon Baraliakos, Juergen Braun, Atul Deodhar, et al.
Rheumatology (Oxford, England)|May 3, 2018
Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patientsWalter P Maksymowych, Désirée van der Heijde, Xenofon Baraliakos, et al.
Pageof 28

Showing results (141-150 of 272) with videos related to

Sort By:
Pageof 28
Rheumatology and Therapy|September 11, 2024
Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 TrialsJeffrey R Curtis, Atul Deodhar, Enrique R Soriano, et al.
Arthritis and Rheumatism|December 30, 2009
Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trialClifton O Bingham, R John Looney, Atul Deodhar, et al.
Annals of the Rheumatic Diseases|September 2, 2016
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 StudyJoachim Sieper, Atul Deodhar, Helena Marzo-Ortega, et al.
The Permanente Journal|August 2, 2016
Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care SettingJeffrey R Curtis, Leslie R Harrold, Maryam M Asgari, et al.
Clinical Rheumatology|August 27, 2025
Prevalence of axial spondyloarthritis (axSpA) in patients treated for chronic back pain in chiropractic clinics: the oregon chiropractic axial spondyloarthritis study (ORCAS)Atul Deodhar, Shireesh Bhalerao, Sonam Kiwalkar, et al.
Lancet (London, England)|June 13, 2018
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyAtul Deodhar, Alice B Gottlieb, Wolf-Henning Boehncke, et al.
Arthritis Research & Therapy|March 22, 2022
Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitisM Elaine Husni, Atul Deodhar, Sergio Schwartzman, et al.
Rheumatology and Therapy|February 23, 2023
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing SpondylitisVictoria Navarro-Compán, Xenofon Baraliakos, Marina Magrey, et al.
RMD Open|October 1, 2019
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension studyXenofon Baraliakos, Juergen Braun, Atul Deodhar, et al.
Rheumatology (Oxford, England)|May 3, 2018
Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patientsWalter P Maksymowych, Désirée van der Heijde, Xenofon Baraliakos, et al.
Pageof 28